A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer. Article
Full Text via DOI: 10.1200/JCO.2021.39.15_suppl.TPS3156
Web of Science: 000708120306235
International Collaboration